Abstract
Gadolinium-based contrast agents can increase the accuracy and expediency of an MRI examination. However the benefits of a contrast-enhanced scan must be carefully weighed against the well-documented risks associated with administration of exogenous contrast media. The purpose of this review is to discuss commercially available gadolinium-based contrast agents (GBCAs) in the context of pediatric radiology. We discuss the chemistry, regulatory status, safety and clinical applications, with particular emphasis on imaging of the blood vessels, heart, hepatobiliary tree and central nervous system. We also discuss non-GBCA MRI contrast agents that are less frequently used or not commercially available.
Similar content being viewed by others
References
Bhargava R, Hahn G, Hirsch W et al (2013) Contrast-enhanced magnetric resonance imaging in pediatric patients: review and recommendations for current practice. Magn Reson Insights 6:95–111
Young IR (2000) Methods in biomedical magnetic resonance imaging and spectroscopy. Wiley, Chichester
Edelman GM, Hesselink JR, Zlatkin MB et al (2006) Clinical magnetic resonance imaging — volume 3. Elsevier Health, St. Louis
Boros E, Gale EM, Caravan P (2015) MR imaging probes: design and applications. Dalton Trans 44:4804–4818
Carr DH, Bydder GM, Weinmann H-J et al (1984) Intravenous chelated gadolinium as a contrast agent in NMR imaging of cerebral tumors. Lancet 323:484–486
Caravan P, Ellison JJ, McMurry TJ et al (1999) Gadolinium(III) chelates as MRI contrast agents: structure, dynamics and applications. Chem Rev 99:2293–2352
Caravan P, Farrar CT, Frullano L et al (2009) Influence of molecular parameters and increasing magnetic field strength on relaxivity of gadolinium- and manganese-based T1-contrast agents. Contrast Media Mol Imaging 4:89–100
Gale EM, Atanasova I, Blasi F et al (2015) A manganese alternative to gadolinium for MRI contrast. J Am Chem Soc 137:15548–15557
Caravan P (2006) Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chem Soc Rev 35:512–523
Caravan P (2009) Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action. Acc Chem Res 42:851–862
Caravan P, Cloutier NJ, Greenfield MT et al (2002) The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates. J Am Chem Soc 124:3152–3162
Vander Elst L, Chapelle F, Laurent S et al (2001) Stereospecific binding of MRI contrast agents to human serum albumin: the case of Gd-(S)-EOB-DTPA (Eovist) and its ® isomer. J Biol Inorg Chem 6:196–200
Shen Y, Goerner FL, Snyder C et al (2015) T1 Relaxivities of Gadolinium-Based Magnetic Resonance Contrast Agents in Human Whole Blood at 1.5, 3, and 7 T. Investig Radiol 50:330–338
Morcos SK (2008) Extracellular gadolinium contrast agents: Differences in stability. Eur J Radiol 66:175–179
Laurent S, Vander Elst L, Henoumon C et al (2010) How to measure the transmetallation of a gadolinium complex. Contrast Media Mol Imaging 5:305–308
Laurent S, Vander Elst L, Copoix F et al (2001) Stability of MRI paramagnetic contrast media: a proton relaxometric protocol for transmetallation assessment. Investig Radiol 36:115–122
Aime S, Caravan P (2009) Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. J Magn Res Imaging 30:1259–1267
Jung G, Heindel W, Krahe T et al (1998) Influence of the hepatobiliary contrast agent mangafodipir trisodium (MN-DPDP) on the imaging properties of abdominal organs. Magn Reson Imaging 16:925–931
Nelson SJ, Kurhanewicz J, Vigneron DB et al (2013) Metabolic imaging of patients with prostate cancer using hyperpolarized [1-13C]pyruvate. Sci Transl Med 5:198ra108
Sieber MA, Steger-Hartmann T, Lengsfeld P et al (2009) Gadolinium-based contrast agents and NSF: evidence from animal experience. J Magn Res Imaging 30:1268–1276
Jost G, Lenhard DC, Sieber MA et al (2016) Signal increase on unenhanced T1-weighted images in the rat brain after repeated, extended doses of gadolinium-based contrast agents comparison of linear and macrocyclic agents. Investig Radiol 51:83–89
Anderson P (2015) FDA okays MRI contrast agent (Gadavist) in infants. Medscape. http://www.medscape.com/viewarticle/837629. Accessed 15 December 2016
Ellis JH, Davenport MS, Dillman JR et al (2015) ACR manual on contrast media v10.1. American College of Radiology, Reston
Grobner T (2006) Gadolinium — a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21:1104–1108
Marckmann P, Skov L, Rossen K et al (2006) Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17:2359–2362
U.S. Food & Drug Administration (2009) Joint meeting of the Cardiovascular and Renal Drugs and Drug Safety and Risk Management Advisory Committee. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: FDA briefing document. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM190850.pdf. Accessed 15 December 2016
Yang L, Krefting I, Gorovets A et al (2012) Nephrogenic systemic fibrosis and class labeling of gadolinium-based contrast agents by the Food and Drug Administration. Radiology 265:248–253
Swan SK, Lambrecht LJ, Townsend R et al (1999) Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment. Investig Radiol 34:443–448
Marcos SK, Thomsen HS, Dawson P (2006) Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)? Clin Radiol 61:905–906
Swan SK, Baker JF, Free R et al (1999) Pharmacokinetics, safety, and tolerability of gadoversetamide injection (OptiMARK) in subjects with central nervous system or liver pathology and varying degrees of renal function. J Magn Res Imaging 9:317–321
Schuhmann-Giampieri G, Krestin G (1991) Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. Investig Radiol 26:975–979
European Medicines Agency (2010) Assessment report for gadolinium-containing contrast agents. Procedure no. EMEA/H/A-31/1097. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/gadolinium_31/WC500099538.pdf. Accessed 15 December 2016
Davenport MS, Dillman JR, Cohan RH et al (2013) Effect of abrupt substitution of gadobenate dimeglumine for gadopentetate dimeglumine on rate of allergic-like reactions. Radiology 266:773–782
Hahn G, Sorge I, Gruhn B et al (2009) Pharmacokinetics and safety of gadobutrol-enhanced magnetic resonance imaging in pediatric patients. Investig Radiol 44:776–783
Kunze CW, Mentel H-J, Krishnamurthy R et al (2016) Pharmacokinetics and safety of macrocyclic gadobutrol in children aged younger than 2 years including term newborns in comparison to older populations. Investig Radiol 51:50–57
Kanda T, Kawaguchi H (2013) Hyperintense dentate nucleas and globus pallidus on unenhanced T1-weighted MR images are associated with gadolinium-based contrast media. Neuroradiology 55:1268–1269
Kanda T, Ishii K, Kawaguchi H et al (2014) High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 270:834–841
Kanda T, Fukusato T, Matsuda M et al (2015) Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology 276:228–232
Kanda T, Osawa M, Oba H et al (2015) High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration. Radiology 275:803–809
Radbruch A, Weberling LD, Kieslich PJ et al (2015) Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology 275:783–791
Miller JH, Houchun HH, Pokorney A et al (2015) MRI brain signal intensity changes of a child during the course of 35 gadolinium contrast examinations. Pediatrics 136:e1637–e1640
Murata N, Gonzalez-Cuyar LF, Murata K et al (2016) Macrocyclic and other non–group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and bone tissue: preliminary results from 9 patients with normal renal function. Investig Radiol 51:447–453
Maximova N, Gregori M, Zennaro F et al (2016) Hepatic gadolinium deposition and reversibility after contrast agent-enhanced MR imaging of pediatric hematopoietic stem cell transplant recipients. Radiology 281:418–426
Chavhan GB, Babyn PS, John P et al (2015) Pediatric body MR angiography: principles, techniques, and current status in body imaging. AJR Am J Roentgenol 205:173–184
Grist TM, Thornton FJ (2005) Magnetic resonance angiography in children: technique, indications, and imaging findings. Pediatr Radiol 35:26–39
Miyazaki M, Akahane M (2012) Non-contrast enhanced MR angiography: established techniques. J Magn Reson Imaging 35:1–19
Chung T (2005) Magnetic resonance angiography of the body in pediatric patients: experience with a contrast-enhanced time-resolved technique. Pediatr Radiol 35:3–10
Rofsky NM, Lee VS, Laub G et al (1999) Abdominal MR imaging with a volumetric interpolated breath-hold examination. Radiology 212:876–884
Cornfield D, Mojibian H (2009) Clinical uses of time-resolved imaging in the body and peripheral vascular system. AJR Am J Roentgenol 193:W546–W557
Lewis M, Yanny S, Malcolm PN (2012) Advantages of blood pool contrast agents in MR angiography: a pictorial review. J Med Imaging Radiat Oncol 56:187–191
Krishnamurthy R, Bahouth SM, Muthapillai R (2016) 4D contrast-enhanced MR angiography with the keyhole technique in children: technique and clinical applications. Radiographics 36:14
Sundareswaran K, Frakes D, d Zelicourt D et al (2008) Comparison of power losses, hepatic flow splits, and vortex sizes in different fontan types using non invasive phase contrast magnetic resonance imaging. Circulation 118:S1057
Makowski M, Wiethoff A, Uribe S et al (2011) Congenital heart disease: cardiovascular MR imaging by using an intravascular blood pool contrast agent. Radiology 260:680–688
Hsiao A, Lustig M, Alley M et al (2012) Rapid pediatric cardiac assessment of flow and ventricular volume with compressed sensing parallel imaging volumetric cine phase-contrast MRI. AJR Am J Roentgenol 198:W250–W259
Gabbour M, Schnell S, Jarvis K et al (2015) 4-D flow magnetic resonance imaging: blood flow quantification compared to 2-D phase-contrast magnetic resonance imaging and Doppler echocardiography. Pediatr Radiol 45:804–813
Ordovas K, Higgins C (2011) Delayed contrast enhancement on MR images of myocardium: past, present, future. Radiology 261:358–374
Simonetti O, Kim R, Fieno D et al (2001) An improved MR imaging technique for the visualization of myocardial infarction. Radiology 218:215–223
Kellman P, Wilson J, Xue H et al (2012) Extracellular volume fraction mapping in the myocardium, part 1: evaluation of an automated method. J Cardiovasc Magn Reson 14:63
Tandon A, Villa CR, Hor KN et al (2015) Myocardial fibrosis burden predicts left ventricular ejection fraction and is associated with age and steroid treatment duration in Duchenne muscular dystrophy. J Am Heart Assoc 4:e001338
O'Hanlon R, Grasso A, Roughton M et al (2010) Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 56:867–874
Moon J, Messroghli D, Kellman P et al (2013) Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson 15:92
Gerber B, Raman S, Nayak K et al (2008) Myocardial first-pass perfusion cardiovascular magnetic resonance: history, theory, and current state of the art. J Cardiovasc Magn Reson 10:18
Manso B, Castellote A, Dos L et al (2010) Myocardial perfusion magnetic resonance imaging for detecting coronary function anomalies in asymptomatic paediatric patients with a previous arterial switch operation for the transposition of great arteries. Cardiol Young 20:410–417
Prakash A, Powell A, Krishnamurthy R et al (2004) Magnetic resonance imaging evaluation of myocardial perfusion and viability in congenital and acquired pediatric heart disease. Am J Cardiol 93:657–661
Friedrich M, Sechtem U, Schulz-Menger J et al (2009) Cardiovascular magnetic resonance in myocarditis: a JACC white paper. J Am Coll Cardiol 53:1475–1487
Banka P, Robinson J, Uppu S et al (2015) Cardiovascular magnetic resonance techniques and findings in children with myocarditis: a multicenter retrospective study. J Cardiovasc Magn Reson 17:96
Ferreira V, Piechnik S, Dall'Armellina E et al (2012) T1-mapping has a high diagnostic performance in patients presenting with acute myocarditis: a cardiovascular magnetic resonance study. Heart 98:A52–A53
Ferreira V, Piechnik S, Dall'Armellina E et al (2013) T(1) mapping for the diagnosis of acute myocarditis using CMR: comparison to T2-weighted and late gadolinium enhanced imaging. JACC Cardiovasc Imaging 6:1048–1058
Seale MK, Catalano OA, Saini S et al (2009) Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. Radiographics 29:1725–1748
Tran VT, Vasanawala S (2013) Pediatric hepatobiliary magnetic resonance imaging. Radiol Clin N Am 51:599–614
Guglielmo FF, Mitchell DG, Gupta S (2014) Gadolinium contrast agent selection and optimal use for body MR imaging. Radiol Clin N Am 52:637–656
Nandwana SB, Moreno CC, Osipow MT et al (2015) Gadobenate dimeglumine administration and nephrogenic systemic fibrosis: is there a real risk in patients with impaired renal function? Radiology 276:741–747
Lauenstein T, Ramirez-Garrido F, Kim YH et al (2015) Nephrogenic systemic fibrosis risk after liver magnetic resonance imaging with gadoxetate disodium in patients with moderate to severe renal impairment: results of a prospective, open-label, multicenter study. Investig Radiol 50:416–422
Vaneckova M, Herman M, Smith MP et al (2015) The benefits of high relaxivity for brain tumor imaging: results of a multicenter intraindividual crossover comparison of gadobenate dimeglumine with gadoterate meglumine (The BENEFIT study). AJNR Am J Neuroradiol 36:1589–1598
Rigsby CK, Popescu AR, Nelson P et al (2015) Safety of blood pool contrast agent administration in children and young adults. AJR Am J Roentgenol 205:1114–1120
Rigsby CK, Hilpipre N, McNeal GR et al (2014) Analysis of an automated background correction method for cardiovascular MR phase contrast imaging in children and young adults. Pediatr Radiol 44:265–273
Farmakis SG, Khanna G (2014) Extracardiac applications of MR blood pool contrast agent in children. Pediatr Radiol 44:1598–1609
Cha S (2006) Dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in pediatric patients. Neuroimaging Clin N Am 16:137–147
Wang Y-XJ, Hussain SM, KRestin GP (2001) Superparamaganetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol 11:2319–2331
Wang Y-XJ (2011) Superparamagnetic iron oxide based MRI contrast agents: current status of clinical application. Quant Imaging Med Surg 11:35–40
Hope MD, Hope TA, Zhu C et al (2015) Vascular imaging with ferumoxytol as a contrast agent. AJR Am J Roentgenol 205:W366–W374
Bellin M-F, Roy C, Kinkel K et al (1998) Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles —initial clinical experience. Radiology 207:799–808
Li S-D, Huang L (2008) Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 5:496–504
Arami H, Khandhar A, Liggitt D et al (2015) In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem Sci Rev 44:8576–8607
Li W, Tutton S, Vu AT et al (2004) First-pass contrast-enhanced magnetic resonance angiography in humans using ferumoxytol, a novel ultrasmall superparamagnetic iron oxide (USPIO)-based blood pool agent. J Magn Res Imaging 21:46–52
Harisinghani MG, Berentsz J, Hahn PF et al (2003) Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348:2491–2499
Heesakkers RAM, Jager GJ, Hövels AM et al (2009) Prostate cancer: detection of lymph node metastases outside the routine surgical area with ferumoxtran-10 - enhanced MR imaging. Radiology 251:408–414
Prince MR, Zhang HL, Chabra SG et al (2003) A pilot investigation of new superparamagnetic iron oxide (ferumoxytol) as a contrast agent for cardiovascular MRI. J Xray Sci Technol 11:231–240
Ruangwattanapaisarn N, Hsiao A, Vasanawala SS (2015) Ferumoxytol as an off-label contrast agent in body 3T MR angiography: a pilot study in children. Pediatr Radiol 45:831–839
Luhar A, Khan S, Finn JP et al (2016) Contrast-enhanced magnetic resonance venography in pediatric patients with chronic kidney disease: initial experience with ferumoxytol. Pediatr Radiol 46:1332–1340
Thompson EM, Guillaume DJ, Dósa E et al (2012) Dual contrast perfusion MRI in a single imaging session for assessment of pediatric brain tumors. J Neurooncol 109:105–114
Schiller B, Bhat P, Sharma A (2014) Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period. Clin Ther 36:70–83
Muehe AM, Fang D, von Eyben R et al (2016) Safety report of ferumoxytol for magnetic resonance imaging in children and young adults. Investig Radiol 51:221–227
Lauffer RB (1987) Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: theory and design. Chem Rev 87:901–927
Elizondo G, Fretz CJ, Stark DD et al (1991) Preclinical evaluation of MnDPDP: new paramagnetic hepatobiliary contrast agent for MR imaging. Radiology 178:73–78
Hamm B, Vogl TJ, Branding G et al (1992) Focal liver lesions: MR imaging with MnDPDP initial clinical results in 40 patients. Radiology 182:167–174
Vogl TJ, Hamm B, Schnell B et al (1993) Mn-DPDP enhancement patterns of hepatocellular lesions on MR images. J Magn Res Imaging 3:51–58
Gallez B, Bacic G, Swartz HM (1996) Evidence for the dissociation of the hepatobiliary MRI contrast agent Mn-DPDP. Magn Reson Med 35:14–19
Toft KG, Hustvedt SO, Grat D et al (1997) Metabolism and Pharmacokinetics of MnDPDP in man. Acta Radiol 38:677–689
Crossgrove J, Zheng W (2004) Manganese toxicity upon overexposure. NMR Biomed 17:544–553
O'Neal SL, Zheng W (2015) Manganese toxicity upon overexposure: a decade in review. Curr Environ Health Rep 2:315–328
Aschner JL, Aschner M (2005) Nutritional aspects of manganese homeostasis. Mol Asp Med 26:353–362
Yang Y, Schühle DT, Dai G et al (2012) 1H chemical shift magnetic resonance imaging probes with high sensitivity for multiplex imaging. Contrast Media Mol Imaging 7:276–279
Harvey P, Blamire AM, Wilson JI et al (2013) Moving the goal posts: enhancing the sensitivity of PARASHIFT proton magnetic resonance imaging and spectroscopy. Chem Sci 4:4251–4258
Mizukami S, Takikawa R, Sugihara F et al (2008) Paramagnetic relaxation-based 19F MRI probe to detect protease activity. J Am Chem Soc 130:794–795
Tirotta I, Mastropietro A, Cordiglieri C et al (2014) A superfluorinated molecular probe for highly sensitive in vivo19F‐MRI. J Am Chem Soc 136:8524–8527
Sherry AD, Woods M (2008) Chemical exchange saturation transfer contrast agents for magnetic resonance imaging. Annu Rev Biomed Eng 10:391–411
Liu G, Gilad AA, Bulte JWM et al (2010) High-Throuput Screening of Chemical Exchange Saturation Transfer MR Contrast Agents. Contrast Media Mol Imaging 5:162–170
Brindle KM, Bohndiek SE, Gallagher FA, Kettunen MI (2011) Tumor imaging using hyperpolarized 13C magnetic resonance spectroscopy. Magn Reson Med 66(2):505–19
Svenningsen S, Kirby M, Starr D et al (2013) Hyperpolarized 3He and 129Xe MRI: differences in asthma before bronchodilation. J Magn Res Imaging 38:1521–1530
Qing K, Ruppert K, Jiang Y et al (2014) Regional mapping of gas uptake by blood and tissue in the human lung using hyperpolarized xenon-129 MRI. J Magn Reson Imaging 39:346–359
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
Dr. Gale has provided consulting services to Collagen Medical LLC, and has equity in Reveal Pharmaceuticals Inc. Dr. Caravan has research funding from Pfizer, Biogen and Agilent, has provided consulting services to Guerbet, and has equity in Collagen Medical LLC, Factor 1A LLC and Reveal Pharmaceuticals Inc. Drs. Rao, McDonald, Winfeld, Fleck and Gee have no potential conflicts of interest to disclose.
Rights and permissions
About this article
Cite this article
Gale, E.M., Caravan, P., Rao, A.G. et al. Gadolinium-based contrast agents in pediatric magnetic resonance imaging. Pediatr Radiol 47, 507–521 (2017). https://doi.org/10.1007/s00247-017-3806-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00247-017-3806-0